It was published on Jan. 6 in JAMA Internal Medicine. DoxyPEP is a new strategy for preventing STIs that involves taking a dose of doxycycline, a common and well-tolerated antibiotic medication, ...
Both studies in JAMA Internal Medicine supported the rising profile of doxyPEP as a way to counter the epidemic of syphilis, gonorrhea, and chlamydia infections, even if the data ...
The early rollout of doxyPEP — a dose of the antibiotic doxycycline after sex — has contributed to a decline in sexually transmitted infections in Northern California, according to a pair of studies ...
While the use of PrEP has helped drop the rates of HIV infections, instances of syphilis and chlamydia among queer men have been skyrocketing, but a new study shows that doxyPEP may be the answer to ...
This is one of the first real-world studies to show the effectiveness of the tactic called doxyPEP, for doxycycline post-exposure prophylaxis, researchers said. Related 20% of people aged 15 to 49 ...
Quarterly syphilis rates decreased from 1.7% prior to doxyPEP availability to 0.3% afterward, while quarterly chlamydia rates declined from 9.6% to 2%. Quarterly gonorrhea infections dropped from 10.2 ...
Doxycycline postexposure prophylaxis has the potential to substantially reduce real-world population-level incidence of ...
The rates of chlamydia and syphilis declined dramatically among individuals living with HIV who were prescribed doxycycline postexposure prophylaxis, according to results of a retrospective cohort ...
A new treatment for sexually-transmitted diseases seems to be slowing an STI epidemic — but not everyone can get it ...
It tends to be less effective at preventing gonorrhoea. DoxyPEP can be taken by those living with HIV and people who are HIV-negative. This approach may not be effective for cisgender women or people ...
This is one of the first real-world studies to show the effectiveness of the tactic called doxyPEP, for doxycycline post-exposure prophylaxis, researchers said. “Interventions that are effective ...